Professor  GARRY NOLAN  Ph.D.

5 DECADES  of  DEDICATED  RESEARCH  &  INNOVATION;

Single-Cell & Spatial Omics Technologies, Immunology, Hematopoiesis, Cancer & Leukemia

Autoimmunity, Inflammation & Infectious Disease, Computational Biology & Network Modeling

Technology Commercialization & Entrepreneurship

Founding Biotech Ventures

Emerging Topics & Public Advocacy for UAP/UFO Science

Material Science of UAP

Garry completed his Ph.D. training under Leonard Herzenberg and conducted postdoctoral research with Nobel Laureate Dr. David Baltimore, where he was involved in the first cloning and characterization of NF-κB p65/RelA and helped develop rapid retroviral production systems.

Published over 350 research papers, holds 50 U.S. patents, and has been recognized as one of the top 25 inventors at Stanford University. His research spans a wide range of fields, including hematopoiesis, cancer and leukemia, autoimmunity and inflammation, as well as computational and systems-level approaches to immunology and cellular networks.

A central focus of his work is to advance understanding of both normal immune function and pathological processes such as trauma, infection, inflammation, and cancer. His research explores the complex interactions between leukemias, solid tumors, and the immune system—work that aims to uncover new insights leading to improved disease management and clinical outcomes.

In addition to his academic contributions, he is a vocal advocate for the translation of public and private investment in basic research into tangible benefits for society. He is the founder of Rigel Inc. (NASDAQ: RIGL) and Nodality, Inc., a diagnostics development company, and serves on the boards of several biotech and technology firms. He was Chair of the Scientific Advisory Board at DVS Sciences, and co-founded BINA, a sequencing analysis company acquired by Roche for $110 million. He is also a co-founder of multiple companies across single-cell analysis, pathology imaging, atomic imaging, and artificial intelligence, including Apprise, Akoya, Scale, Cellformatica, Health Universe, IonPath, and StarDustX.

Dr. Nolan is also the co-founder and Executive Director of the Board of the Sol Foundation, a leading center for research into Unidentified Aerial Phenomena (UAP). The foundation convenes experts from academia, government, and other disciplines to conduct rigorous, multidisciplinary studies on UAP and their broader implications. Its mission includes advancing public and policy-relevant research, advising governmental and corporate stakeholders, and educating the public on the scientific, societal, and cosmological significance of UAP discoveries. Learn more at www.thesolfoundation.org.

The Rachford and Carlota A. Harris Professor  

Department of Pathology,  Stanford School of Medicine